Outlook Therapeutics Inc
NASDAQ:OTLK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Outlook Therapeutics Inc
NASDAQ:OTLK
|
US |
|
S
|
Scotgold Resources Ltd
LSE:SGZ
|
AU |
|
J
|
Jaykay Enterprises Ltd
BSE:500306
|
IN |
Balance Sheet
Balance Sheet Decomposition
Outlook Therapeutics Inc
Outlook Therapeutics Inc
Balance Sheet
Outlook Therapeutics Inc
| Sep-2014 | Sep-2015 | Sep-2016 | Sep-2017 | Sep-2018 | Sep-2019 | Sep-2020 | Sep-2021 | Sep-2022 | Sep-2023 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
2
|
9
|
2
|
3
|
2
|
8
|
13
|
14
|
17
|
23
|
0
|
|
| Cash |
2
|
9
|
2
|
3
|
2
|
8
|
13
|
14
|
17
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
23
|
0
|
|
| Total Receivables |
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
2
|
3
|
1
|
2
|
5
|
5
|
7
|
10
|
8
|
12
|
|
| Total Current Assets |
3
|
15
|
6
|
4
|
3
|
14
|
18
|
22
|
28
|
31
|
27
|
|
| PP&E Net |
8
|
18
|
19
|
16
|
18
|
3
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
8
|
18
|
19
|
16
|
18
|
3
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
2
|
4
|
6
|
9
|
12
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
0
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Total Assets |
12
N/A
|
35
+202%
|
25
-27%
|
21
-18%
|
22
+7%
|
17
-23%
|
20
+15%
|
23
+16%
|
29
+25%
|
32
+13%
|
29
-10%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
3
|
12
|
5
|
11
|
4
|
2
|
2
|
2
|
3
|
7
|
8
|
|
| Accrued Liabilities |
3
|
6
|
6
|
7
|
6
|
5
|
8
|
2
|
3
|
3
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
13
|
7
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
11
|
16
|
6
|
5
|
5
|
5
|
4
|
1
|
11
|
36
|
29
|
|
| Other Current Liabilities |
3
|
4
|
3
|
5
|
4
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Total Current Liabilities |
20
|
37
|
20
|
29
|
32
|
20
|
16
|
7
|
20
|
47
|
43
|
|
| Long-Term Debt |
4
|
6
|
3
|
13
|
4
|
3
|
1
|
11
|
0
|
0
|
0
|
|
| Minority Interest |
3
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
8
|
19
|
8
|
9
|
8
|
4
|
0
|
1
|
0
|
0
|
59
|
|
| Total Liabilities |
35
N/A
|
64
+81%
|
31
-52%
|
51
+68%
|
43
-16%
|
28
-35%
|
17
-39%
|
18
+8%
|
20
+9%
|
47
+136%
|
102
+118%
|
|
| Equity | ||||||||||||
| Common Stock |
22
|
65
|
0
|
3
|
5
|
6
|
1
|
2
|
2
|
3
|
0
|
|
| Retained Earnings |
45
|
94
|
147
|
186
|
216
|
254
|
290
|
343
|
409
|
468
|
543
|
|
| Additional Paid In Capital |
0
|
0
|
142
|
152
|
190
|
238
|
291
|
346
|
415
|
451
|
470
|
|
| Total Equity |
24
N/A
|
29
-21%
|
5
+82%
|
31
-494%
|
21
+32%
|
11
+48%
|
3
N/A
|
5
+63%
|
9
+90%
|
14
N/A
|
73
-406%
|
|
| Total Liabilities & Equity |
12
N/A
|
35
+202%
|
25
-27%
|
21
-18%
|
22
+7%
|
17
-23%
|
20
+15%
|
23
+16%
|
29
+25%
|
32
+13%
|
29
-10%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
1
|
6
|
9
|
11
|
13
|
24
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|